Rochester, MI, USA, July 17, 2023 – Caeregen Therapeutics announced today that it has been awarded a $1.4 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen™),...
Rochester, MI, USA and Halle, Germany, June 28, 2023 – Caeregen Therapeutics, a regenerative medicine therapeutics company and Wacker Biotech, a contract development and manufacturing organization (CDMO), will collaborate on the development and production of CTR-107 (Noregen™), a novel regenerative therapeutic for the treatment of retinal-related...
First potential FEVR therapy to obtain U.S. FDA Rare Pediatric Disease Designation Designation provides Noregen™ Rare Pediatric Disease Priority Review Voucher Eligibility Follows earlier Orphan Drug Designations in FEVR by both US FDA and EC EMA Caeregen Therapeutics today announced the U.S. Food and Drug Administration (FDA) designated Noregen™ for treatment...
Data presented on promising activity of Noregen™, first potential regenerative therapy for retinal diseasesFollows 1Q2022 U.S. FDA and EU EMA Orphan Drug Designation (ODD) for Noregen™ in Familial Exudative Vitreoretinopathy (FEVR) May 3, 2022, Denver, CO and Rochester, MI – Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company...
A Novel Regenerative Therapy For The Treatment Of Familial Exudative Vitreoretinopathy (FEVR) First potential FEVR therapy to obtain U.S. Food and Drug Administration Orphan Drug DesignationFollows Orphan Medicinal Product Designation by European Commission based European Medicines Agency Committee for Orphan Medicinal Products Positive Opinion January 27, 2022,...
Late phase fluorescein angiographic findings which predict capillary drop out and drug treatment which can lead to capillary preservation...